Form 4: Pfizer Executive Alexandre de Germay Reports Acquisition of Stock and Stock Appreciation Rights

Executive Vice President Alexandre de Germay reports acquisition of Pfizer stock and stock appreciation rights on February 27, 2024.

Summary

• Alexandre de Germay, an Executive Vice President at Pfizer Inc., reported changes in beneficial ownership on February 28, 2024.
• On February 27, 2024, de Germay acquired 74,377 shares of Pfizer common stock through a grant of restricted stock units, which are subject to vesting requirements.
• De Germay also acquired 89,533 stock appreciation rights (SARs) that will be settled in Pfizer common stock on February 27, 2029, subject to vesting requirements.
• Additionally, 79,111 stock appreciation rights (SARs) were acquired that will be settled in Pfizer common stock on February 27, 2031, subject to vesting requirements.
• The exercise price for both sets of SARs is $26.89.
• Following these transactions, de Germay directly owns 74,377 shares of common stock, 89,533 SARs expiring on February 27, 2029, and 79,111 SARs expiring on February 27, 2031.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of executive compensation. The acquisition of shares and SARs could be seen as a slightly positive sign of the executive's confidence, but it's not a strong indicator.

Positives

• The acquisition of stock and stock appreciation rights by a high-ranking executive could be interpreted as a positive signal about the executive's confidence in the company's future performance.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the restricted stock units and stock appreciation rights suggest a multi-year commitment from the executive.

Industry Context

Executive compensation packages often include stock and stock appreciation rights to align management's interests with those of shareholders. This filing is a routine disclosure of such compensation.

Comparison to Industry Standards

• Stock grants and SARs are common components of executive compensation packages in the pharmaceutical industry, used to incentivize long-term performance.
• Companies like Johnson & Johnson, Merck, and AbbVie also utilize similar equity-based compensation strategies for their executives.
• The specific amounts and vesting schedules vary based on company size, performance, and individual executive roles.

Stakeholder Impact

• The acquisition of shares and SARs by an executive could have a minor positive impact on shareholder sentiment.

Key Dates